Inhibrx Set to Unveil Phase 2 Data for INBRX-106 in Head and Neck Cancer
Event summary
- Inhibrx to present primary endpoint results from Phase 2 HexAgon study on September 8, 2026.
- Study evaluates INBRX-106 (hexavalent OX40 agonist) + pembrolizumab vs. pembrolizumab alone in first-line HNSCC.
- Target population: PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent patients.
- Webcast available for 60 days post-event; slide deck incorporated into investor materials.
The big picture
Inhibrx's upcoming data readout comes amid growing interest in OX40 agonists as potential partners for checkpoint inhibitors like pembrolizumab. The study's design targets a high-unmet-need population in first-line HNSCC, where treatment options remain limited. Success could position INBRX-106 as a key asset in Inhibrx's pipeline, particularly following its restructuring and focus on novel biologic formats.
What we're watching
- Clinical Efficacy
- Whether INBRX-106 combination demonstrates superior efficacy over pembrolizumab monotherapy in HNSCC.
- Regulatory Pathway
- The pace at which positive data could accelerate INBRX-106's development timeline.
- Competitive Positioning
- How results may differentiate Inhibrx's multivalent approach from traditional bivalent antibodies.